SCHEMBL6137004

SCHEMBL6137004

O=C(O)c1ccc(-n2nc(-c3ccccc3)c3ccc4ccccc4c32)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G10 O15496 1/20 0.51
RORC P51449 3/20 0.48
HPGD P15428 2/20 0.48
HTT P42858 1/20 0.48
NPC1 O15118 3/20 0.46
RAB9A P51151 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
TP53 P04637 1/20 0.46
MAPT P10636 1/20 0.46
HSP90AA1 P07900 1/20 0.45
NFKB1 P19838 1/20 0.45
NFKB2 Q00653 1/20 0.45
RELA Q04206 1/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
CA12 O43570 1/20 0.44
CA9 Q16790 1/20 0.44
PTGER1 P34995 1/20 0.43
KDM6B O15054 1/20 0.43
ABCC4 O15439 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6136884 0.79 RORC (0.66) RORCHPGDHTTPTGER1RARG
SCHEMBL22214621 0.76 LMNA (0.43) MAPTNPSR1ALDH1A1
SCHEMBL8135748 0.76 MAPK1 (0.47) PLA2G10HPGDHTTSMN1; SMN2MAPT
SCHEMBL732894 0.75 RORC (0.50) RORCHPGDNPC1RAB9ASMN1; SMN2
SCHEMBL22214754 0.75 LMNA (0.43) MAPTNPSR1ALDH1A1
SCHEMBL22214624 0.75 LMNA (0.43) MAPTNPSR1ALDH1A1
SCHEMBL6137028 0.74 RORC (0.59) RORCHPGDHTTPTGER1RARG
SCHEMBL22206283 0.73 LMNA (0.44) HTTNPC1RAB9AMAPTMEN1
Hydrochloric Acid SCHEMBL6136946 0.73 RORC (0.57) RORCHPGDHTTNPC1RAB9A
SCHEMBL22214625 0.73 ALDH1A1 (0.41) HPGDMAPTMEN1KMT2ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050227299-A1 Fluorescent dyes (AIDA) for solid phase and solution phase screening AUER MANFRED 2005-10-13 US disclosed
EP-1140856-B1 FLUORESCENT DYES FOR SOLID PHASE AND SOLUTION PHASE SCREENING NOVARTIS AG (CH) 2005-04-27 EP disclosed
EP-1140856-A1 FLUORESCENT DYES FOR SOLID PHASE AND SOLUTION PHASE SCREENING Novartis AG (CH) 2001-10-10 EP disclosed
US-20010005752-A1 Fluorescent dyes (AIDA) for solid phase and solution phase screening AUER MANFRED (AT) 2001-06-28 US disclosed
US-6207831-B1 A BENZOPYRAZOLE COMPOUND NOVARTIS AG (CH) 2001-03-27 US disclosed
WO-2000037448-A1 FLUORESCENT DYES FOR SOLID PHASE AND SOLUTION PHASE SCREENING NOVARTIS AG (CH) 2000-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010005752-A1 Fluorescent dyes (AIDA) for solid phase and solution phase screening SLC43A1, CUTA, ANXA1 PLA2G10 2795/4885RORC 4824/4885HPGD 4341/4885
US-20050227299-A1 Fluorescent dyes (AIDA) for solid phase and solution phase screening SLCO1A2, ABCG2, SLCO1B1 PLA2G10 2539/4885RORC 3437/4885HPGD 2745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.